Intramuscular administration of mesenchymal stromal cells in a cat with asthma: case report.

Intramuscular MSCs may be safe, effective alternative for corticosteroid-dependent feline asthma.

This case report describes the novel use of intramuscular mesenchymal stromal cell (MSC) therapy in a 7-year-old cat with severe asthma. The patient presented with chronic clinical signs including coughing, apathy, vomiting, and dependence on corticosteroids and bronchodilators. The cat received three IM injections of 1 × 10⁶ MSCs per kg body weight at 30-day intervals. Following treatment, the cat experienced sustained clinical improvement with successful discontinuation of corticosteroids and bronchodilators without recurrence of asthma attacks during 2 years of follow-up. Additional benefits included resolution of frequent vomiting and improved appetite with 0.6 kg weight gain. Quality-of-life assessment demonstrated significant improvement in vitality and comfort (P < .05). No adverse effects were documented. This case represents the first reported use of intramuscular MSC delivery for asthma in any species, offering a promising alternative therapeutic strategy to minimize long-term corticosteroid dependence in feline asthma patients while improving overall quality of life.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.